The STEP (Semaglutide Treatment Effect in People with obesity) 1 trial was a randomized, placebo-controlled trial that evaluated the efficacy of once-weekly subcutaneous (SC) semaglutide 2.4 mg plus lifestyle interventions in adults with obesity without diabetes (n = 1961)
Incretin-based therapies are increasingly recognized not only for their weight-loss effects but also for their broader health benefits
Additionally, the combined expression of IL-17A, IL-17F, IL-21, retinoic acid receptor-related orphan receptor C (RORC), and transforming growth factor (TGF)- mRNA significantly predicted the rachmilewitz endoscopic index (REI), with IL-17A and IL-17F being associated with increased and decreased REI, respectively [67]
By advocating for accessible treatments, supporting individuals on their weight loss journeys, and pushing for systemic change, Ivim Health is dedicated to sustaining the momentum that has led to this historic shift in obesity rates
The longest retatrutide data we have right now is 48 weeks from Phase 2
As metabolic health solutions evolve from treatment toward prevention, developers will face increasing scrutiny around long-term safety, substantiation of health claims, patient stratification, and real-world outcomes
